ReviewJournal of hepatology2016
Overview of hepatitis B viral replication and genetic variability.
Review in Journal of hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 228 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
228 citing papers in PubMed, 5 syntheses or guidelines pooled it, 416 citations in OpenAlex.
- The incidence of hepatocellular carcinoma and clearance of hepatitis B surface for CHB patients in the indeterminate phase: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2023Pooled it
- Interplay between Cellular Autophagy and Hepatitis B Virus Replication: A Systematic Review.Cells · 2020Pooled it
- Acupuncture for chronic hepatitis B.The Cochrane database of systematic reviews · 2019Pooled it
- Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B.The Cochrane database of systematic reviews · 2019Pooled it
- Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B.The Cochrane database of systematic reviews · 2019Pooled it
- Effect of high-intensity interval training in patients with chronic hepatitis B and hepatic steatosis: A randomised controlled trial.PloS one · 2026Trial
- Trial
- Trial
- Serum miR-375 Levels Are Closely Related to Disease Progression from HBV Infection to HBV-Related Hepatocellular Carcinoma.BioMed research international · 2020Trial
- The long noncoding RNA MAPKAPK5-AS1 promotes the formation of hepatitis B virus cccDNA by modulating the expression of NABP1.Virulence · 2026Article
- Single-Cell Hepatitis B Sequencing Reveals Distinct Viral Infection Events Consistent With Superinfection.The Journal of infectious diseases · 2026Article
- Comparison of Peg-INF plus TDF versus TDF Monotherapy in Indeterminate-phase Chronic Hepatitis B Patients with High HBsAg levels, HBeAg-negative status, and Normal ALT Levels.Journal of clinical and translational hepatology · 2026Article
- Article
- Clinical significance and mutation analysis of HBsAg and Anti-HBs coexistence in Chronic Hepatitis B.Virus research · 2026Article
- Spatiotemporal heterogeneity of neutrophil extracellular traps in hepatocellular carcinoma microenvironment and targeted therapy progress.Journal of translational medicine · 2026Review
- Reconciling fast Hepatitis B evolutionary rates with ancient co-divergence.bioRxiv : the preprint server for biology · 2026Article
- Article
- Accuracy of Diagnostic Investigations in Monitoring Hepatitis B Virus Infection: Strengths, Limitations, and Emerging Biomarkers.International journal of molecular sciences · 2026Review
- Epidemiology and genotypic profiling of hepatitis B virus among febrile individuals in a high-endemic Ghanaian setting.BMC infectious diseases · 2026Article
- ZNF638 represses the transcription of HBV closed circular DNA involving HUSH complex-mediated histone modifications of epigenetic silencing.Cell communication and signaling : CCS · 2026Article
168 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
Abstract
Chronic infection with hepatitis B virus (HBV) greatly increases the risk for liver cirrhosis and hepatocellular carcinoma (HCC). HBV isolates worldwide can be divided into ten genotypes. Moreover, the immune clearance phase selects for mutations in different parts of the viral genome. The outcome of HBV infection is shaped by the complex interplay of the mode of transmission, host genetic factors, viral genotype and adaptive mutations, as well as environmental factors. Core promoter mutations and mutations abolishing hepatitis B e antigen (HBeAg) expression have been implicated in acute liver failure, while genotypes B, C, subgenotype A1, core promoter mutations, preS deletions, C-terminal truncation of envelope proteins, and spliced pregenomic RNA are associated with HCC development. Our efforts to treat and prevent HBV infection are hampered by the emergence of drug resistant mutants and vaccine escape mutants. This paper provides an overview of the HBV life cycle, followed by review of HBV genotypes and mutants in terms of their biological properties and clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.